Dennis Meletiche, PharmD

Articles by Dennis Meletiche, PharmD

Reconsidering the Economic Value of Multiple Sclerosis Therapies

ByTiffany Shih, PhD,Craig Wakeford, MA,Dennis Meletiche, PharmD,Jesse Sussell, PhD,Adrienne Chung, PhD,Yanmei Liu, MS,Jin Joo Shim, MS,Darius Lakdawalla, PhD

October 26th 2016

Availability of multiple sclerosis (MS) therapies provides substantial value to the currently healthy (who may contract MS in the future), particularly when treatment is fully covered by insurance.

Latest Updated Articles

Reconsidering the Economic Value of Multiple Sclerosis Therapies
October 26th 2016

Dennis Meletiche, PharmD

Articles by Dennis Meletiche, PharmD

Reconsidering the Economic Value of Multiple Sclerosis Therapies

Latest Updated Articles

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access